Reviva Pharmaceuticals Holdings

Historical 13F Holders

Symbol
RVPH
CUSIP
76152G100
All holders as of
Q1 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 76152G100 since 12/18/2024, newest first.

Filer % of Class Filed
683 Capital Management, LLC 13G/A Amendment 1
3.0% 2/17/2026
Event 12/31/2025
Integrated Core Strategies (US) LLC 13G/A Amendment 1
2.8% 1/16/2026
Event 12/31/2025
Parag Saxena 13D/A Amendment 12
5.2% 12/22/2025
Event 12/18/2025
683 Capital Management, LLC 13G
5.4% 9/29/2025
Event 9/22/2025
Parag Saxena 13D/A Amendment 11
6.2% 9/24/2025
Event 9/22/2025
Bhat Laxminarayan 13D/A Amendment 6 3.8% 9/24/2025
Event 9/22/2025
CVI Investments, Inc. 13G/A Amendment 1
4.9% 8/14/2025
Event 6/30/2025
Tang Capital Management LLC 13G/A Amendment 4
4.8% 8/14/2025
Event 6/30/2025
Highbridge Capital Management LLC 13G 9.9% 8/14/2025
Event 6/30/2025
CVI Investments, Inc. 13G
5.9% 7/1/2025
Event 6/26/2025
Parag Saxena 13D/A Amendment 10
8.7% 7/1/2025
Event 6/27/2025
Bhat Laxminarayan 13D/A Amendment 5 5.2% 7/1/2025
Event 6/27/2025
Tang Capital Management LLC 13G/A Amendment 3
7.8% 5/15/2025
Event 3/31/2025
Schonfeld Strategic Advisors LLC 13G/A Amendment 1 2.8% 2/14/2025
Event 12/31/2024
CVI Investments, Inc. 13G/A Amendment 1
4.9% 2/7/2025
Event 12/31/2024
Parag Saxena 13D/A Amendment 9
12.4% 1/31/2025
Event 12/18/2024
CVI Investments, Inc. 13G
7.2% 12/23/2024
Event 12/16/2024
Bhat Laxminarayan 13D/A Amendment 4 6.8% 12/20/2024
Event 12/18/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q1 1 4.00 k $714.00
2025 Q4 55 11.2 M $3.13 M
2025 Q3 48 9.49 M $3.50 M
2025 Q2 55 14.3 M $5.45 M
2025 Q1 57 7.33 M $6.95 M
2024 Q4 51 7.79 M $14.1 M
2024 Q3 38 9.95 M $14.9 M
2024 Q2 38 6.87 M $8.77 M
2024 Q1 37 5.62 M $21.2 M
2023 Q4 51 5.27 M $27.1 M
2023 Q3 41 2.66 M $13.0 M
2023 Q2 32 2.65 M $15.5 M
2023 Q1 29 1.38 M $5.76 M
2022 Q4 29 1.35 M $5.73 M
2022 Q3 24 921 k $1.65 M
2022 Q2 17 1.87 M $2.05 M
2022 Q1 21 1.90 M $4.68 M
2021 Q4 16 2.64 M $7.62 M
2021 Q3 13 2.60 M $10.5 M
2021 Q2 13 2.65 M $12.8 M
2021 Q1 9 586 k $3.37 M
2020 Q4 4 360 k $3.15 M